首页> 外文OA文献 >Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

【2h】

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

机译：Nivolumab VS调查仪在头部和颈部的复发或转移性鳞状细胞癌中的选择：2年的Checkmate 141的长期存活更新，通过肿瘤PD-L1表达分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Robert L. Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A. Dimitrios Colevas; Lisa Licitra; Kevin J. Harrington; Stefan Kasper; Everett E. Vokes; Caroline Even; Francis Worden; Nabil F. Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Mark Lynch; Vijayvel Jayaprakash; Li Li; Maura L. Gillison;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [J] . Ferris Robert L., Blumenschein George Jr., Fayette Jerome, Oral oncology . 2018 ,第期

机译：Nivolumab VS调查员在头部和颈部的复发或转移性鳞状细胞癌中的选择：2年的肿瘤PD-L1表达分析了2年的Checkmate 141的疗效更新
2. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [J] . Ferris R. L., Blumenschein G. R., Fayette J., International Journal of Radiation Oncology, Biology, Physics . 2018 ,第5期

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）
3. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [J] . Ferris R. L., Blumenschein G. R., Fayette J., International Journal of Radiation Oncology, Biology, Physics . 2018 ,第5期

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）
4. Low Dose Photofrin? PDT for Recurrent In-Situ Squamous Cell Tumors of the Head and Neck [C] . R R Allison, Austerlitz C, Sheng C, World congress of the International Photodynamic Association . 2009

机译：低剂量Photofrin？ PDT治疗头颈部复发性原位鳞状细胞瘤
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [O] . Robert L. Ferris, George Blumenschein Jr., Jerome Fayette, -1

机译：Nivolumab vs研究者在头颈部复发或转移性鳞状细胞癌中的选择：CheckMate 141的2年长期生存更新并通过肿瘤PD-L1表达进行分析
7. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [O] . R.L. Ferris, G.R. Blumenschein, J. Fayette, 2018

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

著录项

相似文献

相关主题

期刊订阅